HGS-ETR1, a fully human agonistic monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trial.

被引：0
|
作者：
Hirte, HW
Hotte, SJ
Chen, EX
Siu, L
Le, LH
Lo, L
MacLean, M
Iacobucci, A
Fox, NL
Oza, AM
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] Juravinski Canc Ctr, Hamilton, ON, Canada
[3] Human Genome Sci Inc, Rockville, MD USA
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9104S / 9104S
页数：1
相关论文
共 50 条
  • [1] HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trial.
    Hotte, SJ
    Hirte, HW
    Chen, EX
    Le, LH
    Corey, A
    Maclean, M
    Iacobucci, A
    Fox, NL
    Oza, AM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 204S - 204S
  • [2] A phase 1 study of HGS-ETR1, a fully human agonistic monoclonal antibody to the TRAIL-R1, in combination with gemcitabine and cisplatin in subjects with advanced solid malignancies.
    Mom, CH
    Sleijfer, S
    Gietema, JA
    Sneller, V
    Fox, NL
    Lo, L
    Uges, DR
    Loos, W
    de Vries, EG
    Verweij, J
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9117S - 9117S
  • [3] Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
    Trarbach, T.
    Moehler, M.
    Heinemann, V.
    Koehne, C-H
    Przyborek, M.
    Schulz, C.
    Sneller, V.
    Gallant, G.
    Kanzler, S.
    BRITISH JOURNAL OF CANCER, 2010, 102 (03) : 506 - 512
  • [4] Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
    T Trarbach
    M Moehler
    V Heinemann
    C-H Köhne
    M Przyborek
    C Schulz
    V Sneller
    G Gallant
    S Kanzler
    British Journal of Cancer, 2010, 102 : 506 - 512
  • [5] Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer
    von Pawel, Joachim
    Harvey, Jimmie H.
    Spigel, David R.
    Dediu, Mircea
    Reck, Martin
    Cebotaru, Cristina L.
    Humphreys, Robin C.
    Gribbin, Matthew J.
    Fox, Norma Lynn
    Camidge, D. Ross
    CLINICAL LUNG CANCER, 2014, 15 (03) : 188 - +
  • [6] Results of a phase 2 study of HGS-ETR1, a fully human agonistic monoclonal antibody to TRAIL Receptor 1, in subjects with relapsed or refractory colorectal cancer (CRC)
    Kanzler, S.
    Trarbach, T.
    Heinemann, V.
    Koehne, C. H.
    Sneller, V.
    Bieber, F.
    Galle, P. R.
    Seeber, S.
    EJC SUPPLEMENTS, 2005, 3 (02): : 178 - 178
  • [7] Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL)
    Le, LH
    Hirte, HW
    Hotte, SJ
    Maclean, M
    Iacobucci, A
    Corey, A
    Fox, NL
    Oza, AM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 171S - 171S
  • [8] Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers
    Shin, MS
    Kim, HS
    Lee, SH
    Park, WS
    Kim, SY
    Park, JY
    Lee, JH
    Lee, SK
    Lee, SN
    Jung, SS
    Han, JY
    Kim, H
    Lee, JY
    Yoo, NJ
    CANCER RESEARCH, 2001, 61 (13) : 4942 - 4946
  • [9] HGS-ETR1, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: Results of a phase I and PK study.
    Chow, L. Q.
    Eckhardt, S. G.
    Gustafson, D. L.
    O'Bryant, C.
    Hariharan, S.
    Diab, S.
    Fox, N. L.
    Corey, A.
    Padavic, K.
    Brown, M.
    Cohen, R. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 103S - 103S
  • [10] Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
    Kurbanov, BM
    Geilen, CC
    Fecker, LF
    Orfanos, CE
    Eberle, J
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 125 (05) : 1010 - 1019
12345